Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Stuart J. Wong MD

Stuart J. Wong MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology
Program: Hematology


Publications

  • Neoadjuvant versus induction chemotherapy: more than semantics. (Devisetty K, Wong SJ) J Clin Oncol 2013 Aug 10;31(23):2971-2 PMID 23733777
  • Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. (Johnson A, Tarima S, Wong S, Friedland DR, Runge CL) JAMA Otolaryngol Head Neck Surg 2013 Mar;139(3):256-64 PMID 23429908
  • Retreatment of recurrent head and neck cancer in a previously irradiated field. (Wong SJ, Bourhis J, Langer CJ) Semin Radiat Oncol 2012 Jul;22(3):214-9 PMID 22687946
  • Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). (Ang KK, Chen A, Curran WJ Jr, Garden AS, Harari PM, Murphy BA, Wong SJ, Bellm LA, Schwartz M, Newman J, Adkins D, Hayes DN, Parvathaneni U, Brachman D, Ghabach B, Schneider CJ, Greenberg M, AnnĂ© PR) Cancer 2012 Dec 1;118(23):5783-92 PMID 22569917
  • A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. (de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE) Clin Cancer Res 2012 Apr 15;18(8):2336-43 PMID 22371453
  • Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. (Kharofa J, Choong N, Wang D, Firat S, Schultz C, Sadasiwan C, Wong S) Int J Radiat Oncol Biol Phys 2012 Jun 1;83(2):690-5 PMID 22112556
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 PMID 21775070
  • How does TPF improve survival over PF? (Devisetty K, Wong SJ, Mell LK) Lancet Oncol 2011 May;12(5):419-20; author reply 421-2 PMID 21536218
  • Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. (Wong SJ, Harari PM, Garden AS, Schwartz M, Bellm L, Chen A, Curran WJ, Murphy BA, Ang KK) Cancer 2011 Apr 15;117(8):1679-86 PMID 21472715
  • Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. (Zundel MT, Michel MA, Schultz CJ, Maheshwari M, Wong SJ, Campbell BH, Massey BL, Blumin J, Wilson JF, Wang D) Int J Radiat Oncol Biol Phys 2011 Dec 1;81(5):e825-32 PMID 21300450
  • Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. (Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H) J Clin Oncol 2011 Jan 20;29(3):272-8 PMID 21135270
  • Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. (Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H) J Clin Oncol 2011 Jan 20;29(3):279-86 PMID 21135267
  • Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings. (Murphy BA, Chen A, Curran WJ Jr, Garden AS, Harari PM, Wong SJ, Ang KK) Support Care Cancer 2009 Nov;17(11):1393-401 PMID 19263090
  • Grants and Awards

  • Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (TYKERB) For Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation (#9306028 10/01/2012 - 09/30/2015) Sponsor: American College of Radiology
  • Phase 2 Study to Evaluate the Pharmacokinetics and Drug-Drug Interation of Cetuximab and Ciplatin in Patients with Recurrent or MEtastatic Carcinoma of the Head and Neck (#9306067 12/12/2012 - 12/11/2015) Sponsor: Eli Lilly
  • Chair of the Radiation Therapy Oncology Head and Neck Medical Oncology Subcommittee (#9204792 01/01/2007 - 12/31/2012) Sponsor: American College of Radiology
  • Chair of the Radiation Therapy Oncology Head and Neck Medical Oncology Subcommittee (#9207923 01/01/2013 - 12/31/2013) Sponsor: American College of Radiology
  • A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination w VTX-2337 in Patients w Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (#9306276 10/23/2013 - 10/22/2016) Sponsor: PRA International
  • A Randomized Open-Label Phase II Study of BIBW 2992 Versus Cetuximab in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma After Failure of Platinum-Containing Therapy w/ a Cross-Over Period for Progressing Patients (#9304790 06/30/2008 - 09/12/2012) Sponsor: Boehringer Ingelheim
  • Phase 2 Study to Evaluate the Pharmacokinetics & Drug-Drug Interaction of Cetuximab and Carboplatin in Patients with Recurrent or Metastatic Carcinoma of the Head and Neck. (#9306068 12/12/2012 - 12/11/2015) Sponsor: Eli Lilly
  • Early Therapeutics Development with Phase II Emphasis - N01 CM57018-16 (#9204539 01/01/2007 - 12/31/2007) Sponsor: University of Chicago
  • Phase II Study of Cetuximab & Lenalidomide in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (#9305329 03/18/2011 - 03/17/2014) Sponsor: University of Chicago
  • Phase 3, Randomzied, Open-Label Study Comparing Combo of BRAF Inhibitor, Dabrafenib & MEK Inhibitor, Trametinib to BRAF Inhibitor Vemurafenib in Subjects w Unresectable (Stage 3c) or Metastatic (Stage IV) BRAF V600E/K Mutation + Cutaneous M (#9305898 10/31/2012 - 10/30/2014) Sponsor: GlaxoSmithKline
  • Chair of the Radiation Therapy Oncology Head and Neck Medical Oncology Subcommittee (#9208457 01/01/2014 - 03/31/2014) Sponsor: American College of Radiology